Terumo Corporation · TSE:4543
Terumo — Investor Presentation (May 2022)
16 slides from Terumo's investor presentation, May 12, 2022
Slide 1: Value of the Blood and Cell Technologies Business in the Terumo Growth Strategy
Value of the Blood and Cell Technologies Business in the Terumo Growth Strategy May 12, 2022 Shinjiro Sato President and CEO Terumo Corporation
Slide 2: Safe Harbor for Forward-Looking Statements and Use of Document
Safe Harbor for Forward-Looking Statements and Use of Document Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future even
Slide 3: Balanced Growth With All 3 Companies: Aspiration of GS26
Balanced Growth With All 3 Companies: Aspiration of GS26 Growth potential of each company in our Mid-to-Long term strategy as GS26 Blood and Cell GS26 growth Technologies (Annual Rate) Therapeutic business expansion FY2021* Cardiac Stroke, aortic, peripheral, cancer High-single digit Revenue and Rad
Slide 4: Portfolio Growth Trajectory
Portfolio Growth Trajectory Divergence from shared Acquisitions Cardiac and technologies Intervention Vascular 1960s- 1921 1970s Syringe Infusion Medical Care Solutions Shift to Thermo- disposable meter devices Acquisition Blood and Cell Blood bag Technologies Instruments ©TERUMO CORPORATION 4 / 13
Slide 5: Blood and Cell Technologies Business Growth Trajectory
Blood and Cell Technologies Business Growth Trajectory (Sales revenue; 100M JPY) (3) Growth 1,400 acceleration (2) Return Blood bag price erosion (US) to growth 1,200 Reveos, TACSI (EU) Deceleration Pharmaceuticals, others Cell Processing Spectra Optia (Japan) 1,000 CaridianBCT (US) Therapeutic Aphe
Slide 6: Characteristics of Technologies Portfolio
Characteristics of Blood and Cell Technologies Portfolio Based on inherent Terumo Strengthened position through BCT Competitive with global players strengths acquisition Markets ・・・ Presence globally and in emerging markets Market Leadr in US Competition ・・・ No US giants present Technologies ・・・ Har
Slide 7: 'Ambidextrous' Management: Both Exploitation and Exploration
‘Ambidextrous’ Management: Both Exploitation and Exploration Exploitation ＋ Exploration Apheresis Blood Bag Source plasma Collection Apheresis Automation System from collection to manufacture for cell therapy Blood ＋ Hospitals Pharma ＋ Research centers Company institution ＋ (Hematology dept.) ©TERUM
Slide 8: Expand the Apheresis Principle for New Therapy
Expand the Apheresis Principle for New Therapy ACD-A （Anti Coagulation Liquid） Plasma Collection Bag Examples; • Autologous Cell Transplantation; To collect patient’s peripheral stem cell • Allogeneic Cell Transplantation; Pump To collect peripheral stem cell from a donor • CAR-T Therapy; To collect
Slide 9: Market Potential of New Fields
Market Potential of New Fields $800M scale globally/Annual 8-10% growth constant Source Sustainable market (use for many rare diseases, long life cycle, no generics) Plasma Growth from US key is establishment of collection ecosystem Expand application to autoimmune diseases Increased demand for immu
Slide 10: Innovation That Best Leverages the Core Technology of Centrifugation
Innovation That Best Leverages the Core Technology of Centrifugation Competitive advantage comes from technology that enables faster, more accurate and higher productivity Spectra Optia COBE Spectra Rika Plasma Donation System Component collection system Trima Accel Component collection system Centr
Slide 11: Plasma Innovation Breakthrough
Plasma Innovation Breakthrough The quintessential ‘solutions business’ Built Ecosystem to Address Unmet Needs Beyond supplying a single product • Integrated solution that can revolutionize State-of-art Innovative customer (Ex: CSL) competitiveness automation platform production Build and operate
Slide 12: Strengthen Business Model
Strengthen Business Model Keep the “Razor and Blades” model, but strengthen service Quintessential TBCT model Performance Performance, cost-efficiency Hardware Consumables Circuit Rika Bottle, etc Donor center Service, Software Productivity Value through Safety introducing a digital ecosystem Usabil
Slide 13: Outlook: Sales and Adjusted Operating Profit
Outlook: Sales and Adjusted Operating Profit Copy from 5-Year Growth Strategy with a 10-Year Vision (FY2022-FY2026), “Blood and Cell Technologies company” 12 Sales Adjusted Operating Profit Near double-digit growth Double-digit growth FY16 FY21 FY26 FY16 FY21 FY26 Blood and Beyond Operational Excell
Slide 14: <“TERUMO
<“TERUMO
Slide 15: Synergies with Terumo Group in Advanced Fields
Synergies with Terumo Group in Advanced Fields Invenst in • Made mid-term invest in innovation under the umbrella of Terumo which was Innovation unable during private equity Production • High volume, stable production of consumables technology • Production innovation (automation, labor-saving, digit
Slide 16: Blood and Cell Technologies Business Objectives
Blood and Cell Technologies Business Objectives Aspirations Provide compelling and accessible innovations globally that unlock the power of blood and cells to improve patient outcomes and serve unmet medical needs “Unlocking Potential of Terumo Blood and Cell Technologies” Unique positioning is a na